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Purpose: To evaluate the variables associated with mortality of patients with community-acquired
pneumonia who require mechanical ventilation and to determine the attributable morbidity and intensive
care unit (ICU) mortality of community-acquired pneumonia.
Material and Methods: Retrospective cohort study carried out in 361 ICUs from 20 countries
including 124 patients who required mechanical ventilation on the first day of admission to the
hospital due to acute respiratory failure secondary to severe community-acquired pneumonia. To assess
the factors associated with outcome, a forward stepwise logistic regression analysis was performed,
and to determine the attributable mortality of community-acquired pneumonia, a matched study design
was used.
Results: We found 3 independent variables significantly associated with death in patients with
community-acquired pneumonia requiring mechanical ventilation: simplified acute physiological score
greater than 45 (odds ratio, 5.5 [95% confidence interval, 1.7-12.3]), shock (odds ratio, 5.7 [95%
confidence interval, 1.7-10.1]), and acute renal failure (odds ratio, 3.0 [95% confidence interval,Journal of Critical Care (2005) 20, 230–238Elsevier Inc. All rights reserved.
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Community-acquired pneumonia needing mechanical ventilation 2311.1-4.0]). There was no statistically significant difference in ICU mortality among patients with or
without community-acquired pneumonia (32% vs 35%; P = .59).
Conclusions: Community-acquired pneumonia needing mechanical ventilation is not a disease
associated with higher mortality. The main determinants of patient outcome were initial severity of
illness and the development of shock and/or acute renal failure.
D 2005 Elsevier Inc. All rights reserved.1. Introduction
Community-acquired pneumonia remains a common
and serious illness, in spite of the availability of new
antimicrobials and successful vaccines. Approximately
10% to 36% of patients with community-acquired pneu-
monia who need hospitalization require intensive care unit
(ICU) treatment [1]. Mortality in these patients has been
reported to range from 21% to 58% [2]. Prior inves-
tigations have shown that the requirement for mechanical
ventilation is associated with increased mortality compared
with nonventilated patients [3,4]. There are numerous
studies evaluating clinical outcomes of patients with
community-acquired pneumonia [2], but these studies
included an overall population and the outcome of the
subgroup of patients requiring mechanical ventilation has
not been evaluated in detail.
The objectives of this study were to evaluate variables
associated with mortality of patients with community-
acquired pneumonia who require mechanical ventilation
from the first day of admission to the hospital and to
determine the attributable morbidity and ICU mortality of
community-acquired pneumonia.2. Materials and methods
2.1. Population study
We used the database of a prospective, multicenter,
international cohort of 5183 adult patients who received
mechanical ventilation for more than 12 hours fromMarch 1,
1998, to March 31, 1998, at 361 ICUs [5]. We included in
the study 124 patients (2% of overall population included in
the International Study of Mechanical Ventilation) who
required mechanical ventilation on the first day of admission
to the hospital due to acute respiratory failure secondary to
severe community-acquired pneumonia.
The following information was collected on each patient:
(a) demographic data (sex, age, previous functional status,
weight), date of admission to ICU, and initiating mechan-
ical ventilation; (b) variables related to management (mode
of ventilation, respiratory rate, tidal volume, applied
positive end-expiratory pressure, airway pressures, need
for vasoactive drugs, need for neuromuscular blockers,
arterial blood gas analysis). The arterial blood gases
correspond to the values obtained once daily at approxi-
mately 8:00 am. The ventilator variables correspond to thetime that the arterial blood gases were obtained. The use of
neuromuscular blockers and vasoactive drugs (given for at
least 3 hours in a 24-hour period) was recorded daily for a
maximum of 28 days; and (c) the development of the
following events was assessed daily during the course of
mechanical ventilation for a maximum of 28 days: acute
respiratory distress syndrome, barotrauma, sepsis, renal
failure, hepatic failure, and coagulopathy. A patient was
considered to have any of the above conditions if it was
present for at least 2 consecutive days. The patients were
prospectively followed up for a maximum of 28 days of
mechanical ventilation and/or until discharge from the
hospital and/or death.
Community-acquired pneumonia was defined as an acute
infection of the pulmonary parenchyma that is associated
with at least some symptoms of acute lower respiratory
infection (fever or hypothermia, rigors, sweats, new cough
with or without sputum production or change in color of
respiratory secretions in a patient with chronic cough, chest
discomfort, or the onset of dyspnea), accompanied by the
presence of an acute infiltrate consistent with pneumonia on
a chest radiograph, in a patient not hospitalized within
14 days before onset of symptoms [6].
2.2. Statistical analysis
Results were expressed as mean and SD, median with the
interquartile range, and proportions as appropriate. We used
the Student t test or Mann-Whitney U test to compare
continuous variables and the v2 test or Fisher test to
compare proportions. Significant univariate predictors for
mortality were entered into a forward stepwise logistic
regression analysis, with criteria entry and exit at P b .05
and P b .10, respectively. The model’s goodness of fit was
assessed by the method of Hosmer and Lemeshow.
To determine the attributable morbidity, defined as
duration of mechanical ventilation and ICU length of stay,
and attributable ICU mortality of community-acquired
pneumonia, a matched study design was used, matching
each patient with severe community-acquired pneumonia
needing mechanical ventilation to a mechanically ventilat-
ed patient but without community-acquired pneumonia
from our database. The matched variables were variables
that we have reported to be associated with mortality in
mechanically ventilated patients [5]: (a) variables present
at the beginning of mechanical ventilation (age, simplified
acute physiological score [SAPS II], limited activity as
previous functional status); (b) variables related to patient
Table 2 Factors associated with ICU mortality in patients






Variables present at the beginning of mechanical ventilation
Age (y), mean (SD) 62 (18) 58 (18) .24
E. Tejerina et al.232management (use of vasoactive drugs, use of neuromus-
cular blockers, plateau pressure N35 cm H2O); and (c)
complications developing over the course of mechanical
ventilation (acute respiratory distress syndrome, sepsis,
shock, renal failure, hepatic failure, coagulopathy, and ratio
of Pao2 to Fio2). The variability range for matching age
was F10 years and for SAPS II was F10 points.
SAPS II (points),
mean (SD)
57 (18) 40 (12) b.001
Female, n (%) 29 (34.5) 13 (32.5) .82
Prior functional state
(limited activity), n (%)
18 (45%) 38 (45%) .98
Arterial blood gases previous to mechanical ventilation,
mean (SD)
Arterial pH 7.29 (0.11) 7.29 (0.11) .85
Paco2 51 (21) 52 (19) .77
Ratio of Pao2 to Fio2 141 (71) 172 (89) .05
Variables related with management
Use of neuromuscular
blockers, n (%)
9 (22.5) 9 (11) .10
Ventilatory management, mean (SD)
First day of mechanical ventilation
Tidal volume (mL/kg) 9 (2) 9 (2) .87
Applied PEEP (mL/kg) 5 (4) 5 (3) .92
Plateau pressure (cm H2O) 23 (4) 23 (5) .98
Last day of mechanical ventilation
Tidal volume (mL/kg) 9 (2) 9 (2) .79
Applied PEEP (mL/kg) 6 (4) 5 (2) .25
Plateau pressure (cm H2O) 25 (7) 23 (3) .10
Arterial blood gases, mean (SD)
First day of mechanical ventilation
Arterial pH 7.38 (0.09) 7.38 (0.09) 1.00
Paco2 (mm Hg) 39 (12) 40 (13) .64
Ratio of Pao2 to Fio2 144 (69) 179 (80) .03
Last day of mechanical ventilation
Arterial pH 7.37 (0.10) 7.40 (0.04) .05
Paco2 (mm Hg) 40 (9) 39 (6) .61
Ratio of Pao2 to Fio2 174 (78) 213 (74) .013. Results
Characteristics of patients who were diagnosed with
community-acquired pneumonia needing mechanical venti-
lation are shown in Table 1. Among these, 40 (32%) patients
died during the ICU stay and 46 (37%) patients died during
the hospital stay. Among surviving patients (n = 84), the
destinations at hospital discharge were as follows: home
(74%), nursing home (11%), acute facility (7%), and other
destiny (9%).
3.1. Prognosis factors
Nonsurviving patients had a greater severity of illness at
ICU admission and more shock, acute renal failure, and
coagulopathy over the course of mechanical ventilation
(Table 2).
Although a trend was observed toward a better evolution
in patients who survived, there were no significant differ-
ences in any blood gases parameter except for ratio of Pao2
to Fio2. Significant differences were found in this parameter
before mechanical ventilation (mean ratio of Pao2 to Fio2,
141 F 71 for nonsurvivors vs 172 F 89 for survivors;
P = .05), at first day (mean ratio of Pao2 to Fio2, 144 F 69
vs 179 F 80; P = .03) and last day of mechanical ventilation
(mean ratio of Pao2 to Fio2, 174 F 78 vs 213 F 74;
P = .01), and in the degree of improving oxygenation (mean
difference between last and previous value of ratio of Pao2Table 1 Characteristics of patients with community-acquired
pneumonia who needed mechanical ventilation (N = 124)
Age (y) 60 (18)
Female sex 42 (34)
SAPS II score (points) 46 (16)
Prior functional state (limited activity) 56 (45)
Use of vasoactive drugs 48 (38)
Use of neuromuscular blockers 17 (14)
Barotrauma 6 (5)
Acute respiratory distress syndrome 8 (6)
Sepsis 17 (14)
Shock 36 (29)
Renal failure 30 (24)
Hepatic failure 10 (8)
Coagulopathy 15 (12)
Metabolic acidosis 6 (5)
Respiratory acidosis 9 (7)
Age and SAPS II score are expressed as mean (SD) and all other values
are expressed as number (%).
Complications developing over the course of mechanical
ventilation, n (%)
Barotrauma 3 (7) 6 (7) 1.00
Acute respiratory distress
syndrome
4 (10) 4 (5) .27
Sepsis 8 (20) 9 (11) .16
Shock 22 (55) 14 (17) b.001
Acute renal failure 18 (45) 12 (14) b.001
Hepatic failure 5 (12.5) 5 (6) .21
Coagulopathy 8 (20) 7 (8) .08
Metabolic acidosis 3 (7.5) 3 (4) .34to Fio2, 34 F 81 in nonsurvivors vs 71 F 96 in survivors;
P = .05).
Multivariate analysis selected 3 independent variables
significantly associated with death: SAPS II greater than
45 (odds ratio, 5.5 [95% confidence interval, 1.7-12.3]),
shock (odds ratio, 5.7 [95% confidence interval, 1.7-10.1]),
and acute renal failure (odds ratio, 3.0 [95% confidence
interval, 1.1-4.0]).
Community-acquired pneumonia needing mechanical ventilation 2333.2. Impact on outcome
Overall, 124 patients with severe community-acquired
pneumonia requiring mechanical ventilation were success-
fully matched to a control patient without community-
acquired pneumonia. Characteristics and outcomes of cases
and controls are shown in Table 3.
There was no statistically significant difference in ICU
mortality among patients with or without community-
acquired pneumonia needing mechanical ventilation (32%
vs 35%; P = .59).
There were no statistically significant differences in
duration of mechanical ventilation (median, 5 days [inter-
quartile range, 3-8 days] vs 4 days [interquartile range,
2-6 days]; P = .23) nor in length of stay (median, 8 days
[interquartile range, 4-15 days] vs 6 days [interquartile
range, 4-13 days]; P = .55) compared with patients without
community-acquired pneumonia.Table 3 Comparison of patients with community-acquired







Variables present at the beginning of mechanical ventilation
Age (y), mean (SD) 60 (18) 59 (17) .83
SAPS II (points),
mean (SD)
46 (16) 45 (16) .82
Prior functional state
(limited activity), n (%)
56 (45) 57 (46) .97
Variables related with management, n (%)
Use of vasoactives 48 (39) 45 (36) .69
Use of neuromuscular
blockers
17 (14) 13 (10) .44
Plateau pressure N35 cm
H2O
6 (5) 4 (3) .52
Complications developing over the course of mechanical
ventilation, n (%)
Barotrauma 6 (5) 5 (4) .76
Acute respiratory distress
syndrome
8 (6) 8 (6) 1.00
Sepsis 17 (14) 17 (14) 1.00
Shock 36 (29) 37 (30) .89
Acute renal failure 30 (24) 32 (26) .77
Hepatic failure 10 (8) 9 (7) .81
Coagulopathy 15 (12) 15 (12) 1.00
Metabolic acidosis 6 (5) 8 (6) .58




5 (3-8) 4 (2-6) .23
Length of stay in the ICU,
median (IQR)
8 (4-15) 6 (4-13) .55
ICU mortality (%) 32 35 .59
IQR indicates interquartile range.4. Discussion
The main findings of our study were that community-
acquired pneumonia requiring mechanical ventilation is not
associated with increase ICU mortality and it did not
prolong either the duration of mechanical ventilation or
the ICU length of stay. Factors significantly associated with
outcome were severity of illness at ICU admission and
development of cardiovascular and renal dysfunction over
the course of mechanical ventilation.
In the outpatient setting, the mortality rate of pneumonia
remains in the range of 1% to 5%, but among patients with
community-acquired pneumonia who require hospitaliza-
tion, the mortality rate increases to 12%, and in specific
populations such as those with bacteremia or patients
requiring admission to ICU, mortality ranges from 21% to
58% [2,7-10]. In our series, the mortality in the ICU of
patients with community-acquired pneumonia requiring
mechanical ventilation was 32%, in the lower range of
those previously reported [7,11,12].
Several studies have analyzed the factors associated
with outcome of patients with community-acquired pneu-
monia [13]. These factors, analyzed in a large systematic
review of the literature [2] and further studies [4,7-15], can
be divided into baseline variables (male sex, age, presence
of coexisting disease, living in a nursing home, underlying
immunosuppression or neoplasm); severity at admission at
hospital (SAPS II N10-13, decreased level of conscious-
ness, tachypnea); factors related with the pneumonia
(radiographic spread of pneumonia or bilateral pulmonary
involvement, aspiration pneumonia, infection caused by
aerobic gram-negative pathogens, the extent of lung injury,
bacteremia, requirement of mechanical ventilation, ineffec-
tive initial antibiotic therapy); and factors related with
extrapulmonary complications (hypothermia, leukopenia,
sepsis, septic shock, renal failure, the number of non-
pulmonary organs that failed). In our cohort of mechan-
ically ventilated patients, the variables associated with
worse outcome were severity of illness on admission at
ICU, shock, and acute renal failure. Although variables
related to oxygenation and pulmonary parameters were not
associated with outcome, we found a trend toward a better
evolution in patients who survived. In a validation study of
American Thoracic Society guideline severity criteria for
community-acquired pneumonia by Ewig et al [7], criteria
reflecting impaired oxygenation (respiratory rate N30/min
and Pao2/Fio2 b250 at admission) were insensitive,
nonspecific, and only weakly associated with mortality
from severe pneumonia. To our knowledge, there are no
previous studies concerning the potential prognostic value
of oxygenation and pulmonary parameters over the whole
course of mechanical ventilation in patients with severe
community-acquired pneumonia. Most studies have eval-
uated hypoxemia at presentation [12,15] or over the first
24 hours of mechanical ventilation [11]. The strengths of
our study were the use of a matching procedure to examine
E. Tejerina et al.234the morbidity and mortality attributable to community-
acquired pneumonia needing mechanical ventilation. In the
present study, we found a control similar to each patient
with community-acquired pneumonia requiring mechanical
ventilation using 12 predefined variables associated with
mortality [5]. We have used data from an international
multicenter database adding to the validity and generaliz-
ability of the obtained results. Our sample size was large
and we only included mechanically ventilated patients,
whereas most of the prior studies of severe community-
acquired pneumonia had mixed populations of ventilated
and nonventilated patients.
We must address several limitations of our study. First,
we have only used clinical criteria to diagnose pneumonia,
and therefore, it has not been ascertained the importance of
other potential determinants of patient outcome such as the
specific microorganism responsible and the adequacy of
initial antimicrobial therapy. In this sense, although some
authors have observed that identifying the etiologic agent
and adjusting treatment both impact patient outcome
[12,16], most studies have demonstrated that causative
agent was not related with outcome [2,17]. Prior antibiotic
administration and adequacy of initial antimicrobial ther-
apy were not considered in this study. Second, in our
series, we did not study, as a prognostic factor, the
radiographic spread of the pneumonia at ICU admission.
However, in the validation study by Ewig et al [7], the two
baseline radiographic criteria (multilobar or bilateral
involvement in chest radiograph) had a high specificity
but remained insensitive and had low positive predictive
values. These observations could be due to the fact that the
correlation of severe pneumonia with the extension of
infiltrates visible on chest radiograph was only moderate.
Third, we only took into account limited activity as prior
functional status and did not account for chronic obstruc-
tive pulmonary disease, alcoholism, diabetes mellitus, and
chronic heart failure, which were shown to be related with
poor outcome in previous studies [4,14]. However, some
other authors did not find comorbidities to influence
outcome [9].
In summary, despite the above-mentioned limitations, we
have found that community-acquired pneumonia needing
mechanical ventilation is not a factor associated with
mortality as compared with patients on mechanical ventila-
tion for other reasons, controlling for potential confounding
variables. And, it does not prolong either duration of
mechanical ventilation or ICU length of stay. We also
observed that initial severity of illness and the development
of shock and/or acute renal failure were main determinants
of patient outcome.Appendix A
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Cortazar (Hospital Universitario de Puebla, Puebla);
R Carrillo Speare (Hospital PEMEX Sur, Me´xico DF);
R Castan˜o (Hospital de Cardiologı´a del CMN, Me´xico
DF); R Corral (Hospital Excel, Tijuana, Baja California);
DM D’Ector Lira (Hospital Metropolitano, Me´xico DF);
G Dı´az Polanco (Hospital de Traumatologı´a Magdalena de
las Salinas, Me´xico DF); JJ Elizalde (Hospital ABC,
Me´xico DF); R Envila Fisher (Hospital Morelos, Chihua-
hua); R Envila Fisher (Hospital Clı´nica del Parque,
Chihuahua); G Franco G (Hospital General de Me´xico,
Me´xico DF); P Garcı´a Balbuena (Hospital General
bFernando Quiroz,Q Me´xico DF); O Gayoso Cruz (Hospital
Regional bAdolfo Lo´pez Mateos,Q Me´xico DF); L Green
(Instituto Nacional de Cancerologı´a, Me´xico DF);
JO Herrera Hoyos (Centro Me´dico Las Ame´ricas, Me´rida);
J Hinojosa (Hospital Angel Lean˜o, Guadalajara); J Huerta
(Clı´nica Londres, Me´xico DF); VA Jua´rez (Hospital
Santelena, Me´xico DF); M Loera (Hospital General
Durango, Durango); C Lo´pez Alzate (Clı´nica del Mar,
Mazatla´n); E Lo´pez Mora (Instituto Nacional de Cardio-
logı´a, Me´xico DF); S Martı´nez Cano (Hospital Hidalgo
Aguascalientes, Aguascalientes); R Mendez Reyes (Hos-
pital Regional 18 de Octubre, Me´xico DF); M Mendoza
(Hospital General de la Villa, Me´xico DF); O Narva´ez
Porras (Instituto Nacional de Enfermedades Respiratorias,
Me´xico DF); E Ortiz (Hospital General Irapuata, Guana-
E. Tejerina et al.236juato); A Padua (Hospital General Torreo´n, Coahuila);
M Poblano (Hospital Jua´rez, Me´xico DF); V Pureco Reyes
(Hospital Regional b20 de Noviembre,Q Me´xico DF);
W Querevalum (Hospital Central Cruz Mexicana, Me´xico
DF); A Quesada (Hospital Ntra Sra de la Salud, San Luis
Potosı´); A Ramı´rez Rivera (Hospital de Enfermedades
Cardiovasculares y del To´rax, IMSS, Monterrey); A Tamariz
(Hospital Clı´nica del Centro, Chihuahua); A Tamariz
(Hospital Central Universitario, Chihuahua); A Vargas
(Hospital General de Pachuca, Pachuca); C Va´zquez
(Hospital General Celaya, Guanajuato). PERU: Coordina-
tor: AM Montan˜ez. M Contardo (Edgardo Rebagliati
Martins–UCI 78B, Lima); E Durand (Guillermo Almenara
Irigoyen-IPPS, Lima); M Manrique (Hospital bJose Casi-
miro Ulloa,Q Lima); JC Meza (Centro Me´dico Naval,
Lima); J Mun˜oz (Edgardo Rebagliati Martins–UCI 28C,
Lima); J Pacheco (Hospital del Apoyo bMarı´a Auxil-
iadora,Q Lima); C Salcedo (Hosp Nacional bDaniel Alcides
Carrio´n,Q Lima); J Silva (Hospital Central FAP, Lima);
C Torres (Hospital Nacional bArzobispo Loayza,Q Lima).
PORTUGAL: Coordinator: J Pimentel. P Amaro (Centro
Hospitalario de Gaia, Gaia); F Faria Qnstituto Portugue´s
de Oncologı´a, Porto); P Freitas (Hospital Fernando da
Fonseca, Amadora-Sintra); P Martins (Hospital Universi-
dade, Coimbra); E Sabino (Hospital Garcı´a de Orta,
Almada); J Salcher (Hospital de San Jose´, UUM, Lisboa);
E Silva (Hospital Senhora do Desterro, Lisboa). SPAIN:
Coordinators: A Esteban, F Frutos-Vivar. JM Allegre
(Hospital Nuestra Sen˜ora del Rosell, Cartagena); S Alonso
(Hospital Joan XXIII, Tarragona); A Alvarez Ruiz
(Hospital General Rio Carrio´n, Palencia); B Alvarez
Sa´nchez (Hospital General, Alicante); MT Antuna (Hospi-
tal de Cabuen˜es, Gijo´n); JM An˜o´n (Hospital Virgen de la
Luz, Cuenca); P Arribas (Hospital 12 de Octubre,
Madrid); A Ayensa (Hospital Virgen de la Salud, Toledo);
A Azca´rate (Hospital Nuestra Sen˜ora de Aranzazu,
Donostia); J Blanco (Hospital del Rı´o Hortega, Valladolid);
GM Besso (Hospital Carlos Haya, Ma´laga); L Cabre´
(Hospital de Barcelona, Barcelona); F Carrizosa (Hospital
General, Je´rez de la Frontera); J Castan˜eda (Hospital
Clı´nico, Valladolid); R de Celis (Hospital de Galdakao,
Galdakao); JA Conesa (Hospital Clı´nico Universitario San
Carlos, Madrid); J Diarte (Complejo Hospitalario, Ciudad
Real); A Dı´az Lamas (Complejo Hospitalario Cristal Pin˜or,
Orense); R Ferna´ndez (Consorci Hospitalari del Parc Taulı´,
Sabadell); M Ferrer (Hospital Clinic i Provincial, Barce-
lona); D Fontaneda (Hospital Virgen Blanca, Leo´n);
P Galdo´s (Hospital General, Mo´stoles); A Garcı´a Jime´nez
(Hospital Arquitecto Marcide, El Ferrol); J Garcı´a Pardo
(Hospital Juan Canalejo, La Corun˜a); J Gener (Hospital
Germans Trias i Pujol, Badalona); JA Go´mez Rubı´
(Hospital Virgen de la Arrixaca, Murcia); G Gonza´lez
Dı´az (Hospital Morales Meseguer, Murcia); S Gonza´lez
Prado (Hospital Josep Trueta, Girona); C Homs (Hospital
General San Jorge, Huesca); J Iban˜ez (Hospital Son
Dureta, Palma de Mallorca); F Jara (Hospital Mutua,Terrassa); M Leo´n (Hospital Amau de Vilanova, Lleida);
A Lloria (Complejo Hospitalario Rebullo´n, Pontevedra);
J Lo´pez Dı´az (Hospital La Paz, Madrid); MaR Lorenzo
(Complejo Hospitalario Materno-Infantil, Las Palmas de
Gran Canaria); S Macı´as (Hospital General, Segovia);
JA Maldonado (Hospital de la Serranı´a, Ronda); J Maynar
(Hospital Santiago Apostol, Vitoria); A Moreno (Complejo
Hospitalario de San Milla´n-San Pedro, Logron˜o); A Mota
(Hospital General Universitario, Elche); T Mut (Hospital
General, Castello´n); M Nolla (Hospital General de
Catalun˜a, Sant Cugat del Valle´s); F Ortega (Hospital
Universitario de Valme, Sevilla); R de Pablo (Hospital
Prı´ncipe de Asturias, Alcala´ de Henares); E Palazo´n
(Hospital General Universitario, Murcia); V Parra (Hospi-
tal de Sagunto, Sagunto); A Peral (Hospital Gregorio
Maran˜o´n, Madrid); JC Portela (Complejo Hospitalario
Xeral-Calde, Lugo); A Ramı´rez (Hospital Nuestra Sen˜ora
de Sonsoles, Avila); JA Ramos (Hospital de Poniente, El
Ejido); P Revuelta (Hospital Universitario de Canarias, La
Laguna); M Rey (Complejo Hospitalario, Santiago de
Compostela); JJ Rodrigo (Hospital Nuestra Sen˜ora del
Pino, Las Palmas de Gran Canaria); JC Rodrı´guez
Borregan (Hospital Marque´s de Valdecilla, Santander);
JA Rodrı´guez Sarria (Hospital General, Elda); A Rubio
(Hospital Ramo´n y Cajal, Madrid); S Ruiz Navarro
(Hospital General Ciudad de Jaen, Jaen); V Sagredo
(Hospital Virgen de la Vega, Salamanca); P Saura (Centre
Hospitalari, Manresa); MJ Serralta (Hospital Universitario
de San Juan, Alicante); JF Solsona (Hospital del Mar,
Barcelona); F Sua´rez Sipmann (Fundacio´n Jime´nez Dı´az,
Madrid); F Taboada (Hospital General de Asturias,
Oviedo); STemprano (Hospital Severo Ochoa, Legane´s);
JP Tirapu (Hospital de Navarra, Pamplona); MaV de la
Torre (Hospital Universitario Virgen de la Victoria,
Ma´laga); P Ugarte (Hospital Marque´s de Valdecilla,
Santander); M Valledor (Hospital de San Agustin, Avile´s);
I Vallverdu´ (Hospital de la Santa Creu i Sant Pau,
Barcelona); C Vaquerizo (Hospital 12 de Octubre, Madrid);
A Vin˜uales (Hospital Lluis Alcanyis, Xa´tiva). TUNISIA:
Coordinator: F Abroug. A Bchiz (Hospital F Bached,
Sousse); J Ben Khelil (Hospital A Mami, Ariana); S Bern
Lakhal (Hospital Rabta, Tunis); B Bouhaja (Hospital
Mongi Slim, La Marsa); H Chelly (Hospital Fattouma
Bourguiba, Sfax); S El Atrous (Hospital Fattouma Bour-
guiba, Monastir); S Ghedira (Hospital Charles Nicolle,
Tunis); H Thabet (CAMUR Tunis). UNITED KINGDOM:
Coordinator: P Nightingale. O Akinpelu (Chorley &
District Hospital, Chorley); D Bardgett (Macclesfield
District General Hospital, Macclesfield); A Batchelor
(Royal Victoria Infirmary, Newcastle upon Tyne); R Beale
(Guy’s Hospital, London); K Burchett (Queen Elizabeth
Hospital, King’s Lynn); N Coleman (North Staffordshire
Royal Infirmary, Stoke on Trent); A Conn (Wansbeck
General Hospital, Ashington); D Edbrooke (Royal Hallam-
shire Hospital, Sheffield); N Fergusson (Countess
of Chester Hospital, Chester); I Grant (Rotherham District
Community-acquired pneumonia needing mechanical ventilation 237Hospital, Rotherham); K Gunning (Addenbrooke’s Hospi-
tal, Cambridge); J Harper (Royal Liverpool University
Hospital, Liverpool); D Higgins (Southend Hospital,
Westcliffe-on-Sea); D Jayson (Southport & Formby
General Hospital, Southport); R Loveland (Wexham Park
Hospital, Slough); L Lynch (Birmingham Heartlands
Hospital, Birmingham); I Macartney (North Manchester
General Hospital, Manchester); E Major (Morriston Hospi-
tal, Swansea); S Mousdale (Blackbum Royal Infirmary,
Blackburn); N Soni (Chelsea and Westminster Hospital,
London); D Watson (Walsgrave Hospital, Walsgrave).
URUGUAY: Coordinator: C Rodrigo . H Bagnulo
(Maciel, Montevideo); C Rodrigo (Asociacio´n Espan˜ola
Primera, Montevideo); M Rodrı´guez (Hospital de Pay-
sandu´, Montevideo). UNITED STATES: Coordinator: A
Anzueto. SM Aguayo (Atlanta VA Medical Center, Deca-
tur); R Alagar (Allegheny General Hospital, Pittsburgh);
RK Albert (Denver Health Medical Center, Denver); TK
Aldrich (Montefiore Hospital & Medical Center, Bronx); K
Amoosa (Medical College of Wisconsin, Milwaukee); N
Anandarao (New York Methodist Hospital, Brooklyn); DC
Angus (University of Pittsburg, Pittsburgh); AC Arroliga
(Cleveland Clinic Foundation, Cleveland); MF Azrieli
(Jacobu Medical Center, Bronx); RA Balk (Medical
Center–203 Jelke, Chicago); PW Bates (Maine Medical
Center, Portland); JF Beamis, Jr (Lahey Hitchcock
Medical Center, Burlington); PE Bellamis (Chs Dept of
Medicine, Los Angeles); DJ Bower (Atlanta VA Medical
Center, Decatur); JP Bradley (William Beaumont Medical
Center, El Paso); RP Byrd, Jr (University of East Tennese,
Jonesboro); VJ Cardenas, Jr (University of Texas Medical
Branch, Galveston); LJ Caruso (University of Florida,
Gainesville); BR Celli (St Elizabeths Medical Center,
Boston); G Clermon (University of Pittsburg, Pittsburgh);
SJ Coole (Carl T. Hayden VA Medical Center, Phoenix);
TA Dillard (Commander MCHJ-MPU, Tacoma); LE Effe-
ren (SUNY Health Science Center, Brooklyn); EW Ely,
Jr (Vanderbilt Lung Transplant Program Newline, Nash-
ville); P Factor (Michael Reese Hospital & Medical Center,
Chicago); TM Fitzpatrick (Walter Reed Army Medical Ctr,
Wash); R Fowler (Wellesley-Central, Toronto); GN Gia-
cooppe, Jr (MCHJ-MPU, Tacoma); KK Guntupalli (Texas
Med Ctr–Ben Taub Gen Hospital, Houston); JB Hall
(University of Chicago, Chicago); ME Hanley (Denver
Medical Center, Denver); MT Haupt (Oregon Health
Science University, Portland); GB Hayes (St Elizabeths
Medical Center, Boston); DE Heiselman (Akron General
Medical Center, Akron); FC Hiller (University of Arkansas
Med Science, Little Rock); JD Hinze (The University of
Texas Health Science Center at San Antonio, San Antonio);
RD Hite (Bowman Gray School of Medicine, Winston-
Salem); RC Hyzy (Henry Ford Hospital, Detroit); A Jubran
(Edward Hines VA Hospital, Hines); CA Kaplan (Univer-
sity of Missouri Columbia, Columbia); MS Karetzky
(Newark Beth Israel Med Ctr, Newark); SA Kurenhy
(Truman Medical Center, Kansas); KV Leeper, Jr (EmoryUniversity School of Medicine, Atlanta); H Levy (University
of New Mexico, Alburquerque); T Lo (Loma Linda
University, Loma Linda); MJ Mador (Buffalo VA Medical
Center, Buffalo); GP Marelich (University of California
Davis Med Ctr, Sacramento); MA Matthay (University
of California, San Francisco); NR McIntyre (Duke
University Medical Center, Durham); SA Metter (Maine
Medical Center, Portland); MS Niederman (Winthrop
University Hospital, Mineola); JR Norman (University of
Mississippi Medical Center, Jackson); DR Oullette (Brooke
Army Medical Center, Fort Sam Houston); P Parsons
(Denver Medical Center, Denver); RG Patel (VA Medical
Center, Jackson); RC Perkins, II (University of Texas
Health Center at Tyler, Tyler); ME Petrini (University of
Mississippi Medical Center, Jackson); MR Pinsky (Univer-
sity of Pittsburg, Pittsburgh); A Pohlman (Edward Hines VA
Hospital, Hines); KW Presberg (Medical College of
Wisconsin, Milwaukee); MP Rocha (Carl T. Hayden VA
Medical Center, Phoenix); W Rodrı´guez Cintron (San Juan
VA Medical Center, San Juan); MJ Rosen(Beth Israel
Medical Center, New York); TM Roy (James Quillen
College of Medicine, Mountain Home); G Rudelfeld
(Harborview Medical Center, Seattle); MJ Rumbak (Univer-
sity Florida, Tampa); SJ Ruoss (Stanford University Medical
Center, Stanford); GA Schmidt (University of Chicago,
Chicago); RF Schneider (Beth Israel Medical Center,
New York); CN Sessler (Medical College of Virginia,
Richmond); CS Shim (Jacobi Medical Center, Bronx); L
Smith (Rush-Presbyterian-St Lukes Medical Center, Chi-
cago); C Strange (MUSC 96 Jonathan Lucas St, Charleston);
JI Sznajder (Michel Reese Hospital & Medical Center,
Chicago); S Tessler (Maimonides Medical Center, Brook-
lyn); V Whyte (Loma Linda University, Loma Linda); L
Wilkelmeyer (Loma Linda University Medical Center MC
1521, Loma Linda); RG Wundering (501 Crews Wing,
Memphis); MH Zaman (The Brookdale Hosp Med Ctr,
Brooklyn); LH Zimmerman (San Francisco VA Medical
Center, San Francisco). VENEZUELA: Coordinator: G
D’Empaire. J Espan˜a (Hospital Universitario, Caracas); F
Pe´rez (Hospital de Clı´nicas, Caracas); R Zerpa (Hospital
Militar, Caracas).
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